We show that intensification of treatment with maraviroc in patients chronically infected with HIV-1 receiving successful long-term ART was not associated with improvements in HIV related morbidity, HIV reservoir, microbial translocation, immune activation or immune exhaustion in either gut or peripheral blood. The measurement of reservoir in both gut and blood longitudinally contributes to a paucity of data in the area.
Background
Despite the huge success of antiretroviral therapy (ART), increased morbidity compared with HIV uninfected individuals continues [1] , particularly in those with a blunted CD4 response to ART [2] . A cure for HIV remains elusive and this is in part due to an inaccessible long-lived pool of latently infected cell; the viral reservoir, which is focused in the gut-associated lymphoid tissue [3] .
Intensification of ART in individuals with suppressed plasma viremia has not consistently reduced viral reservoir or improved immune function [4, 5] . The C-C chemokine receptor type 5 (CCR5) entry inhibitor, maraviroc, is an attractive option as CCR5 receptors are most numerous in the gut and the drug penetrates tissue well [6] . Studies suggest a possible role in increasing CD4 count [7, 8] and reducing immune activation [5, 9] . The gut has been less investigated [4] , with no consensus on microbial translocation [5, 11] or immune activation [11] ].
We investigated the effect of maraviroc intensification on gut immune function and viral reservoir.
Methods

Study Design and recruitment
A prospective study whereby 10 individuals with chronic HIV infection with sustained virological suppression on ARV for >12 months and a CD4+ T cell count below 500 cells/mm, 3 were intensified with a 24-week course of standard dose maraviroc. Blood samples were collected at week 0, 4, 12 and 24. At baseline and week 24, individuals underwent flexible sigmoidoscopy, in which eight-ten rectal biopsies were taken and fixed overnight in 10% normal buffered formalin at 4°C.
Laboratory Tests
Bacterial translocation
Plasma bacterial 16s DNA was quantified by real time PCR [11] . Plasma sCD14 was quantified using the Quantikine Human sCD14 Immunoassay (R&D Systems, Minnesota, USA), according to manufacturer's instructions. All samples were run in duplicate.
HIV Reservoir and residual Viraemia
Low copy viral load was measured with an internally controlled ultrasensitive quantitative real-time RT-PCR able to detect 3 copies/ml. Purified peripheral blood CD4 T cells were analyzed by qPCR for HIV-1 DNA (Total and Integrated) and cell-associated HIV-1 RNA unspliced transcripts (CA-RNA) as reported elsewhere [12] .
For preparation of the gut biopsies for HIV reservoir quantitation, a commercial kit was used (Qiagen, Cat. No. 56404), and the manufacturer's protocol modified as follows to ensure maximum yield of DNA. Biopsy sections were removed from paraffin blocks using a scalpel and placed into 1.5ml micro centrifuge tubes. Samples were washed repeatedly with xylene and ethanol until the precipitate had disappeared, then dried at room temperature. Biopsy sections were incubated at 37°C and DNA extracted using a commercial kit (QIAAMP DNA FFPE Tissue Extraction Kit, ID 56404, Qiagen (Hilden, Germany)). The resulting DNA was eluted into 200ųl and analysed by qPCR using the same assays for peripheral blood CD4 cells detailed above. 
Immunohistochemistry
Rectal biopsy sections were stained for CD4 (goat polyclonal, Novus Biologicals) and CD8 antibodies (rabbit polyclonal, Abcam). Images were analysed in ImageJ and the distribution of cells determined as described by Milano et al [13] .
Statistics
For each outcome measure, the results at baseline and week 24 were compared using the paired Ttest. Wilcoxon rank test was used to assess the impact of tropism on each parameter.
Results:
Patient characteristics
The median age was 46 years. All patients were male with subtype B virus and were receiving two p=0.052). Changes in blood CD4 and CD8 lymphocytes did not correlate with changes in these cells in the gut.
-Bacterial translocation
Between baseline and week 24 there was no significant change in 16s DNA copies (-0.60;p=0.797) or sCD14a (+59.35 p=0.637).
-
HIV reservoir
Neither HIV RNA, HIV DNA (blood or gut) or cellular HIV RNA changed significantly between baseline and week 24 or between baseline and week 12. At baseline gut HIV DNA levels (mean 101806 copies/million cells) were significantly higher than blood (3669 copies/million CD4 T cells) (p=0.017).
-T-cell activation and exhaustion
The level of activation of CD4 + T cells and CD8+ T cells showed non-significant increases from baseline to week 24 in 6 parameters (including CD8+CD38+HLADR;p=0.677) with only %CD8+HLADR (+0.61 p=0.048) increasing significantly. These findings were the same when analysed from baseline to week 12 with only %CD8+ HLADR+ showing a significant change (+0.47; p= 0.001).
Eight out of 10 immune exhaustion markers increased from baseline to week 24 but only CD8% Tigit reached significance (+6.07; p=0.006). This was supported by analysis of week 0 to week 12 (% CD8 Tigit (mean increase +5.82; p=0.004).
Tropism:
Six out 10 individuals had R5 virus. Tropism (R5 v X4 or X4/R5) did not correlate with changes in reservoir, immune activation, immune exhaustion or microbial translocation (all P values >0.05).
Discussion:
In this pilot study, intensification of treatment with maraviroc in patients chronically infected with HIV-1 receiving successful long-term ART with a blunted CD4 immune response was not associated with any overall improvements in surrogate markers of HIV related morbidity (CD4 T cell count or CD4:CD8 ratio), microbial translocation, immune activation or immune exhaustion in either gut or peripheral blood. The isolated significant results in the absence of a broad class-wide effect on T cell exhaustion or activation are potentially interesting but should not be over-interpreted. Furthermore, reservoir did not decline longitudinally either gut or blood. The large gut HIV reservoir supports interventions targeting this compartment; however, the large intra-individual variation means that sample sizes may need to be large. The lack of impact of tropism on the effect of maraviroc on immunological function or reservoir size is novel but limited due to small sample size.
Overall, the study shows no role for maraviroc intensification to improve clinical orimmunological outcomes or to provide complete viral inhibition. The null effect may also reflect that these individuals had more resistant immune dysfunction than intensification with antiretroviral therapy could repair or the short duration of follow up. The study is limited by the small sample size and lack of control group but the detailed analysis particularly of the gut further diminishes the investigation of maraviroc as an agent of intensification. 
